


IFW



CASE LA0074 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Maureen P. O'Brien  
Type or print name

*Maureen P. O'Brien*  
Signature

*August 4, 2004*  
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

GAVAI ET AL.

Confirmation No. 2426

APPLICATION NO: 10/766,086

FILED: JANUARY 27, 2004

FOR: NOVEL 2-SUBSTITUTED CYCLIC AMINES AS CALCIUM SENSING  
RECEPTOR MODULATORS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-5286

Maureen P. O'Brien  
Maureen P. O'Brien  
Attorney for Applicants  
Reg. No. 42,043


Date: August 4, 2004

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.  
LA0074 NP  
APPLICATION NO.  
10/766,086  
APPLICANT  
GAVAI ET AL.  
FILING DATE  
JANUARY 27, 2004

Group



## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,411,890	10/25/83	Momany			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 89/07110	8/10/89	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 89/07111	8/10/89	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 93/04081	3/4/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Brown, E.M. et al., "Cloning and characterization of an extracellular Ca <sup>2+</sup> -sensing receptor from bovine parathyroid", Nature, Vol. 366, pp. 575-580 (1993)
	AS	Bundgaard, H., Chapter 5: "Design and Application of Prodrugs", A Textbook of Drug Design and Development, Harwood Academic Publishers, publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991)
	AT	Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents)

EXAMINER

DATE CONSIDERED


\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.  
LA0074 NP  
APPLICATION NO.  
10/766,086  
APPLICANT  
GAVAI ET AL.  
FILING DATE  
JANUARY 27, 2004

Group



(Use several sheets if necessary)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Edwards, J.P. et al., "Nonsteroidal Androgen Receptor Agonists Based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one", Bioorganic & Medicinal Chemistry Letters, Vol. 9, pp. 1003-1008 (1999)
2AB	Gowen, M. et al., "Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats", The Journal of Clinical Investigation, Vol. 105, No. 11, pp. 1595-1604 (2000)
2AC	Greene, T.W. et al., Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, Inc., publ., pp. xi-xii (table of contents) (1999)
2AD	Hamann, L.G. et al., "Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)", J. Med. Chem., Vol. 42, No. 2, pp. 210-212 (1999)
2AE	Hudlický, M., Oxidations in Organic Chemistry: ACS Monograph 186, American Chemical Society, publ., pp. ix-xiii (table of contents) (1990)
2AF	Larock, R.C., Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, Inc., publ., pp. xiii-xxviii (table of contents) (1989)
2AG	Neer, R.M. et al., "Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis", The New England Journal of Medicine, Vol. 344, No. 19, pp. 1434-1441 (2001)
2AH	Wermuth, C.G. et al., Chapter 31: "Designing Prodrugs and Bioprecursors I: Carrier Prodrugs", The Practice of Medicinal Chemistry, Academic Press, publ., Wermuth, C.G., ed., pp. 671-696 (1996)
2AI	Whitfield, J.F. et al., "Parathyroid Hormone, Its Fragments and Their Analogs for the Treatment of Osteoporosis", Treat. Endocrinol., Vol. 1, No. 3, pp. 175-190 (2002)
2AJ	Zaragoza, F. et al., "(Cyanomethyl)trialkylphosphonium Iodides: Efficient Reagents for the Intermolecular Alkylation of Amines with Alcohols in Solution and on Solid Phase", J. Org. Chem., Vol. 66, No. 7, pp. 2518-2521 (2001)
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

**DOCKET NOTE / REPORT ENTRY**

Case LA0074 NP

Application No. 10/766,086

Present docket date: April 27, 2004

☒ Remove      ☐ Extend to

## FEEES

<input type="checkbox"/>	Application	
<input type="checkbox"/>	Foreign filing petition	
<input type="checkbox"/>	Missing Parts	
<input type="checkbox"/>	Corrections	
<input checked="" type="checkbox"/>	Information Disclosure Statement	<input type="checkbox"/> supplemental
<input checked="" type="checkbox"/>	PTO Form 1449	(no fee)
<input type="checkbox"/>	Claim of Priority	
<input type="checkbox"/>	Drawings	
<input type="checkbox"/>	Amendment / Response	
<input type="checkbox"/>	Terminal Disclaimer	
<input type="checkbox"/>	Appeal	
<input type="checkbox"/>	Address	
<input type="checkbox"/>	Assignment Recordation	
<input type="checkbox"/>	Issue fee	
<input type="checkbox"/>	Abandon application	
<input type="checkbox"/>	Other	

**ATTORNEY:** Jonathan N. Provoost

**DATE:**